UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market

Long a quiet player in the R&D game, UCB made a splash last fall when they announced that their experimental psoriasis drug bimekizumab had defeated J&J’s blockbuster Stelara in a Phase III trial. It was the first of three Phase IIIs meant to launch the candidate into a crowded market dominated by some of the industry’s biggest drugmakers. The second announcement came two months later with a win over AbbVie’s Humira.